You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三葉草生物-B(02197.HK):COVID-19候選疫苗在研究人員主導II期臨試中作為異源加強劑給藥
格隆匯 11-26 06:36

格隆匯11月26日丨三葉草生物-B(02197.HK)發佈公吿,2021年11月26日(北京時間)(即美國東部時間2021年11月25日)啟動一項由研究人員主導的II期試驗,以評估異源及同源COVID-19加強劑的免疫原性及安全性。公司的COVID-19候選疫苗SCB-2019(CpG 1018加鋁佐劑)將作為先前接種過CoronaVac疫苗或重組Covid-19疫苗(阿斯利康╱Fiocruz)的個體的異源加強劑進行評估。

II期試驗是一項研究人員發起的研究,由Instituto D’Or de Pesquisa e Ensino贊助,由比爾及梅琳達‧蓋茨基金會出資,並由巴西衞生部提供支持。該研究是一項雙盲、隨機、對照研究。

該研究預期在巴西的多個研究地點招募約520名健康成人受試者。預計安全性和免疫原性數據將於2022年上半年發佈,其結果將作為優化加強劑量方案的指南進行刊發。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account